接受新辅助全身治疗的乳腺癌患者区域淋巴结病变范围的横断面影像评估
回顾348例接受新辅助全身治疗(NST)后手术的乳腺癌患者,基于治疗前MRI、PET/CT和CT定义影像淋巴结(rN)分期,发现rN3患者中53%存在III级腋窝、37%锁骨上、52%可疑内乳淋巴结;治疗前rN分期与手术时腋窝病变可能性和范围相关(p=0.002),rN3患者手术时61%淋巴结阳性、中位阳性淋巴结5枚、转移灶更大(中位9 vs 6mm)且结外侵犯更常见(61% vs 43%)。
要点
- 治疗前rN3提示III级腋窝、锁骨上或内乳淋巴结受累可能,需在报告中明确标注以辅助手术和放疗规划。
- rN3患者手术时淋巴结阳性率61%、中位阳性淋巴结5枚,高于rN0/rN1患者。
- rN3患者淋巴结转移灶更大(中位9 vs 6mm)且结外侵犯更常见(61% vs 43%)。
核心结论
- 治疗前横断面影像获得的rN分期可反映手术时腋窝淋巴结病变的可能性和范围,可能用于手术和放疗治疗规划及患者预期沟通。
研究设计与样本
- 经IRB批准的回顾性研究,纳入2008年1月至2013年9月在本机构接受NST后手术且影像可回顾的348例乳腺癌患者,复习治疗前乳腺MRI、PET/CT和CT影像及临床病理资料。
关键影像表现/征象
- MRI、CT和PET/CT异常淋巴结表现定义为皮质增厚、FDG高摄取和脂肪门消失。
- rN3病变包括III级腋窝淋巴结47例(53%)、锁骨上淋巴结32例(37%)、可疑内乳淋巴结45例(52%)。
- rN3患者较rN0/rN1患者淋巴结转移灶更大(中位9 vs 6mm)且结外侵犯更常见(61% vs 43%),两者p<0.03。
诊断标准与关键数值
- 治疗前rN分期:rN0 86例(25%)、rN1 173例(50%)、rN3 89例(26%)。
- 治疗前rN分期与手术时腋窝病变可能性和范围相关,p=0.002。
- rN3患者中54/89例(61%)手术时淋巴结阳性,中位(均值)阳性淋巴结5(8±1)枚。
- 诊断时淋巴结阳性者中78/213例(37%)为rN3。
临床应用与阅片要点
- 治疗前横断面影像可识别III级腋窝、锁骨上及可疑内乳淋巴结,报告rN分期有助于手术和放疗规划。
- rN3患者手术时淋巴结阳性率和阳性淋巴结数目更高,可据此与患者沟通预期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Cross-sectional imaging often is performed in breast cancer patients undergoing neoadjuvant systemic therapy (NST) and may identify level III axillary and extra-axillary nodal disease. Our aim was to investigate associations of radiologic nodal staging with pathological N (pN) stage at operation and to explore how this might aid surgical and radiotherapy treatment planning.
MATERIALS AND METHODS: With IRB approval, we reviewed pre-treatment breast MRI, PET/CT, and CT imaging and clinicopathologic data on 348 breast cancer patients with imaging available for review undergoing NST followed by operation at our institution 1/2008-9/2013. We defined abnormal lymph node findings on MRI, CT, and PET/CT to include cortical thickening, FDG-avidity and loss of fatty hilum. Patients were assigned a radiologic nodal (rN) stage based on imaging findings. Statistical analysis was performed using JMP 10.1 software RESULTS: Pre-NST imaging included axillary ultrasound in 338 patients (97%), breast MRI in 305 (88%) and PET/CT or CT in 215 (62%). 213 patients (61%) were biopsy-proven axillary lymph node-positive (LN+) pre-treatment. cT stage was T1 in 9%, T2 in 49%, T3 in 29%, T4 in 12%; median tumor size was 4cm. Pre-treatment rN stage across all the patients was rN0 in 86 (25%), rN1 in 173 (50%), and rN3 in 89 (26%). rN3 disease included level III axillary, supraclavicular and suspicious internal mammary lymph nodes in 47 (53%), 32 (37%) and 45 (52%), respectively. Of patients LN+ at diagnosis, 78 (37%) were rN3. After NST, 162 patients (47%) were node-positive at operation with a median (mean) of 3 (5.9±0.4) positive lymph nodes including 128 of 213 (60%) LN+ at diagnosis. Pre-NST rN stage correlated with the likelihood and extent of axillary disease at operation, p=0.002. Fifty four of 89 rN3 patients (61%) were node-positive at operation with a median (mean) of 5 (8±1) positive nodes. rN3 patients had larger nodal metastases (median 9 vs 6mm) and more frequent extranodal extension (61% vs 43%) than rN0/rN1 patients, both p<0.03.
CONCLUSIONS: Information on rN stage from pre-NST cross-sectional imaging informs the likelihood and extent of axillary nodal disease at operation. This information may be used for surgical and radiotherapy treatment planning and to inform patient expectations.
引用
- Anderson TL, Glazebrook KN, Murphy BL, et al. Cross-sectional imaging to evaluate the extent of regional nodal disease in breast cancer patients undergoing neoadjuvant systemic therapy. Eur J Radiol. 2017. PMID: 28267534. doi:10.1016/j.ejrad.2017.01.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。